Candel Therapeutics, Inc.
CADL
$9.79
$0.323.38%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.32% | 42.19% | 40.60% | 16.57% | 8.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.30% | 94.38% | 50.82% | 30.40% | 2.89% |
| Operating Income | -100.30% | -94.38% | -50.82% | -30.40% | -2.89% |
| Income Before Tax | -220.08% | -109.59% | -5.85% | 78.43% | 189.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -220.08% | -109.59% | -5.85% | 78.43% | 189.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.08% | -109.59% | -5.85% | 78.43% | 189.76% |
| EBIT | -100.30% | -94.38% | -50.82% | -30.40% | -2.89% |
| EBITDA | -104.63% | -98.37% | -52.87% | -31.40% | -3.06% |
| EPS Basic | -197.20% | -35.78% | 38.26% | 87.49% | 151.92% |
| Normalized Basic EPS | -197.16% | -36.13% | 38.26% | 87.49% | 151.93% |
| EPS Diluted | -209.31% | -35.78% | 38.26% | 87.49% | 146.16% |
| Normalized Diluted EPS | -205.46% | -36.13% | 38.26% | 87.49% | 147.84% |
| Average Basic Shares Outstanding | 23.53% | 54.36% | 71.47% | 72.33% | 72.90% |
| Average Diluted Shares Outstanding | 13.87% | 54.36% | 71.47% | 72.33% | 87.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |